

Esther Titos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3613416/publications.pdf>

Version: 2024-02-01

62
papers

4,881
citations

93792

39
h-index

156644

58
g-index

64
all docs

64
docs citations

64
times ranked

7217
citing authors

#	ARTICLE	IF	CITATIONS
1	Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease. <i>Hepatology</i> , 2023, 77, 1303-1318.	3.6	10
2	Albumin protects the liver from tumor necrosis factor α -induced immunopathology. <i>FASEB Journal</i> , 2021, 35, e21365.	0.2	15
3	Implementation of an open-source robotic platform for SARS-CoV-2 testing by real-time RT-PCR. <i>PLoS ONE</i> , 2021, 16, e0252509.	1.1	17
4	Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	47
5	Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF- κ B/NLRP3 inflammasome circuit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28263-28274.	3.3	31
6	FRI-111-Albumin modulates endosomal TLR9 signaling in human peripheral leukocytes: A mechanism for its anti-inflammatory role in ACLF. <i>Journal of Hepatology</i> , 2019, 70, e436.	1.8	3
7	FRI-296-Interaction between the soluble guanylate cyclase and the NLRP3 inflammasome in Kupffer cells: Implications for the anti-inflammatory actions of sGC stimulation in liver. <i>Journal of Hepatology</i> , 2019, 70, e525.	1.8	1
8	PS-145-Albumin protects the liver from tumour necrosis factor alpha-induced cell death. <i>Journal of Hepatology</i> , 2019, 70, e92.	1.8	0
9	Leukocytes from obese individuals exhibit an impaired SPM signature. <i>FASEB Journal</i> , 2019, 33, 7072-7083.	0.2	45
10	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	2.2	134
11	The soluble guanylate cyclase stimulator IWX1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. <i>British Journal of Pharmacology</i> , 2018, 175, 953-967.	2.7	53
12	Oxidized Albumin Triggers a Cytokine Storm in Leukocytes Through P38 Mitogen-Activated Protein Kinase: Role in Systemic Inflammation in Decompensated Cirrhosis. <i>Hepatology</i> , 2018, 68, 1937-1952.	3.6	70
13	Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome. <i>Journal of Leukocyte Biology</i> , 2018, 105, 25-36.	1.5	72
14	Pro-resolving actions of SPM in adipose tissue biology. <i>Molecular Aspects of Medicine</i> , 2017, 58, 83-92.	2.7	33
15	The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress. <i>FASEB Journal</i> , 2017, 31, 5384-5398.	0.2	56
16	Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals. <i>Scientific Reports</i> , 2017, 7, 15724.	1.6	27
17	Polymorphisms in the IL1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. <i>Hepatology</i> , 2017, 65, 202-216.	3.6	39
18	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	3.6	550

#	ARTICLE	IF	CITATIONS
19	Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue. <i>Journal of Immunology</i> , 2016, 197, 3360-3370.	0.4	87
20	Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. <i>European Journal of Pharmacology</i> , 2016, 785, 133-143.	1.7	73
21	Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. <i>Molecular and Cellular Endocrinology</i> , 2016, 419, 44-59.	1.6	64
22	Prostaglandin E2 Exerts Multiple Regulatory Actions on Human Obese Adipose Tissue Remodeling, Inflammation, Adaptive Thermogenesis and Lipolysis. <i>PLoS ONE</i> , 2016, 11, e0153751.	1.1	98
23	Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 536-541.	3.3	185
24	Molecular interplay between δ 5/ δ 6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. <i>Gut</i> , 2014, 63, 344-355.	6.1	107
25	Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. <i>FASEB Journal</i> , 2014, 28, 836-848.	0.2	97
26	Coordinate Functional Regulation between Microsomal Prostaglandin E Synthase-1 (mPGES-1) and Peroxisome Proliferator-activated Receptor δ 3 (PPAR δ 3) in the Conversion of White-to-brown Adipocytes. <i>Journal of Biological Chemistry</i> , 2013, 288, 28230-28242.	1.6	72
27	Omega-3-derived mediators counteract obesity-induced adipose tissue inflammation. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 107, 77-84.	1.0	32
28	Cell-specific PPAR δ 3 deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. <i>Journal of Hepatology</i> , 2013, 59, 1045-1053.	1.8	91
29	Resolution of inflammation in obesity-induced liver disease. <i>Frontiers in Immunology</i> , 2012, 3, 257.	2.2	67
30	New insights into the role of macrophages in adipose tissue inflammation and fatty liver disease: modulation by endogenous omega-3 fatty acid-derived lipid mediators. <i>Frontiers in Immunology</i> , 2011, 2, 49.	2.2	40
31	The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2011, 14, 347-353.	1.3	52
32	Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like Phenotype. <i>Journal of Immunology</i> , 2011, 187, 5408-5418.	0.4	360
33	Role for PPAR δ 3 in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. <i>FASEB Journal</i> , 2011, 25, 2538-2550.	0.2	325
34	The Role of Inflammatory Mediators in Liver Failure. , 2011, , 131-153.		4
35	Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase. <i>Prostaglandins and Other Lipid Mediators</i> , 2010, 92, 54-61.	1.0	22
36	5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor δ 1-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. <i>Hepatology</i> , 2010, 51, 817-827.	3.6	86

#	ARTICLE	IF	CITATIONS
37	Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 1980-1991.	3.6	59
38	5-Lipoxygenase Activating Protein Signals Adipose Tissue Inflammation and Lipid Dysfunction in Experimental Obesity. <i>Journal of Immunology</i> , 2010, 184, 3978-3987.	0.4	139
39	Resolvins, protectins and other lipid mediators in obesity-associated inflammatory disorders. <i>Drug Discovery Today Disease Mechanisms</i> , 2010, 7, e219-e225.	0.8	2
40	Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω -3 fatty acids: a role for resolvins and protectins. <i>FASEB Journal</i> , 2009, 23, 1946-1957.	0.2	511
41	Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. <i>Journal of Lipid Research</i> , 2008, 49, 2513-2523.	2.0	45
42	Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 778-786.	1.3	52
43	Gene expression profiling of renal dysfunction in rats with experimental cirrhosis. <i>Journal of Hepatology</i> , 2006, 45, 221-229.	1.8	3
44	Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. <i>FASEB Journal</i> , 2006, 20, 2537-2539.	0.2	194
45	The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPAR γ activation. <i>FASEB Journal</i> , 2005, 19, 1120-1122.	0.2	129
46	Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. <i>Journal of Leukocyte Biology</i> , 2005, 78, 871-878.	1.5	56
47	The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPAR γ . Influence of albumin. <i>Journal of Hepatology</i> , 2005, 42, 75-81.	1.8	34
48	5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis. <i>Comparative Hepatology</i> , 2004, 3, S19.	0.9	4
49	Cigarette smoke concentrate increases 8-epi-PGF $_{2\alpha}$; and TGF β ₁ secretion in rat mesangial cells. <i>Life Sciences</i> , 2004, 75, 611-621.	2.0	26
50	Increased apoptosis dependent on caspase-3 activity in polymorphonuclear leukocytes from patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2004, 41, 44-48.	1.8	26
51	Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. <i>FASEB Journal</i> , 2003, 17, 1745-1747.	0.2	67
52	Renal Effects of Selective Cyclooxygenase Inhibition in Experimental Liver Disease. <i>Advances in Experimental Medicine and Biology</i> , 2003, 525, 133-136.	0.8	0
53	Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor γ -mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4(LXA4) and ASA-triggered 15-epi-LXA4. <i>FASEB Journal</i> , 2002, 16, 1937-1939.	0.2	58
54	5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: A possible role of cysteinyl-leukotrienes. <i>Gastroenterology</i> , 2002, 122, 387-393.	0.6	96

#	ARTICLE	IF	CITATIONS
55	5-lipoxygenase (5-LO) is involved in Kupffer cell survival. <i>Journal of Hepatology</i> , 2002, 36, 75.	1.8	0
56	Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. <i>British Journal of Pharmacology</i> , 2002, 135, 891-900.	2.7	43
57	Aspirin-Triggered 15-Epi-Lipoxin A4 Biosynthesis in Rat Liver Cells. <i>Advances in Experimental Medicine and Biology</i> , 2002, 507, 199-209.	0.8	0
58	Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. <i>Gastroenterology</i> , 2000, 119, 794-805.	0.6	69
59	Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A ₄ . <i>American Journal of Physiology - Cell Physiology</i> , 1999, 277, C870-C877.	2.1	46
60	Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. <i>Hepatology</i> , 1999, 30, 501-509.	3.6	30
61	Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. <i>Gastroenterology</i> , 1999, 116, 1167-1175.	0.6	61
62	Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1998, 115, 147-156.	0.6	63